ZVA Stock Chart & Stats
€3.91
€0.08(4.09%)
At close: 4:00 PM EST
€3.91
€0.08(4.09%)
Day’s Range― - ―
52-Week Range€1.72 - €4.65
Previous CloseN/A
Volume0.00
Average Volume (3M)364.00
Market Cap
€187.47M
Enterprise Value€218.11
Total Cash (Recent Filing)€185.47M
Total Debt (Recent Filing)€82.33M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Jul 30, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding72,325,455
10 Day Avg. Volume0
30 Day Avg. Volume364
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.76
Revenue Forecast (FY)€54.18M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsStrong TTM gross margins (~79%) indicate Cellectis's gene‑editing and manufacturing deliver high value per revenue unit. A durable gross margin advantage supports partner economics, can fund R&D and manufacturing scale, and improves operating leverage as revenues expand.
Partnership/licensing Revenue ModelCellectis earns revenue via collaborations, licensing, milestone and partner payments rather than product sales. This non‑commercial revenue model creates durable cash inflows tied to development milestones and reduces sole reliance on product launches during lengthy clinical timelines.
Improving Revenue ScaleRevenue has recovered to ~€68M TTM with reported revenue growth (~32.6%), reflecting expanding partner activity and service scale. Sustained top‑line growth would help absorb fixed costs, enhance operating leverage, and reduce dependence on external financing over the medium term.
Bears Say
Persistent Cash BurnMaterial negative operating cash flow and free cash flow (TTM ~-€37.7M / -€39.9M) indicate ongoing cash burn. Unless reduced, this requires external financing, raising dilution risk and constraining investment in trials, manufacturing scale-up, and strategic flexibility over the next several quarters.
Rising Leverage And Shrinking EquityDebt-to-equity rising to ~1.81 alongside a halving of equity reduces balance sheet flexibility. Higher leverage increases fixed obligations and refinancing risk, limiting the company's ability to pursue non‑dilutive partnerships or sustain development spending during lengthy regulatory and clinical cycles.
Deep Operating LossesVery large negative margins and negative EBIT/EBITDA reflect a cost base far above current revenue levels. Structural operating losses suggest profitability is distant without material revenue scale, cost restructuring, or major partner funding, increasing long‑term financing dependency.
Cellectis SA News
ZVA FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was €1.72 and its highest was €4.65 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €187.47M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Jul 30, 2026 which is in 4 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on May 11, 2026. The company reported -€0.153 earnings per share for the quarter, beating the consensus estimate of -€0.221 by €0.068.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.23.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.153 in its last earnings report, beating expectations of -€0.221. Following the earnings report the stock price went down -0.826%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in DE:ZVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.